{
    "organizations": [],
    "uuid": "20701db7670c81f3a34569815a981f7889868bf5",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-herantis-pharma-announces-positive/brief-herantis-pharma-announces-positive-interim-data-from-lymfactin-study-idUSFWN1RT03L",
    "ord_in_thread": 0,
    "title": "BRIEF-Herantis Pharma Announces Positive Interim Data From Lymfactin Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 16 (Reuters) - HERANTIS PHARMA OYJ:\n* REG-HERANTIS PHARMA ANNOUNCES POSITIVE INTERIM DATA FROM LYMFACTIN STUDY IN SECONDARY LYMPHEDEMA\n* PHASE 1 STUDY CONTINUES WITH A 12-MONTH FOLLOW-UP ON PATIENTS. Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-16T14:07:00.000+03:00",
    "crawled": "2018-04-17T12:14:04.024+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "herantis",
        "pharma",
        "oyj",
        "pharma",
        "announces",
        "positive",
        "interim",
        "data",
        "lymfactin",
        "study",
        "secondary",
        "lymphedema",
        "phase",
        "study",
        "continues",
        "patient",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}